share_log

Invivyd | 8-K: Current report

Invivyd | 8-K: Current report

Invivyd | 8-K:重大事件
美股sec公告 ·  05/22 19:09
牛牛AI助理已提取核心訊息
On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of...Show More
On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of growth, particularly as Invivyd commercializes its first product and advances its proprietary tools for variant analysis and predictive modeling. The press release also highlighted the recent emergency use authorization (EUA) granted by the U.S. FDA for Invivyd's monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals, marking a significant milestone for the company.
2024年5月21日,生物製藥公司Invivyd, Inc. 舉行了年度股東大會,選出了七名董事,任期一年。當選董事包括塔姆辛·貝里、薩拉·科特、馬克·埃利亞、醫學博士斯里什蒂·古普塔、克里斯汀·林登布姆、泰倫斯·麥奎爾和凱文·麥克勞克林。此外,股東批准任命普華永道會計師事務所爲該公司截至2024年12月31日的財政年度的獨立註冊會計師事務所。會後,Invivyd發佈了一份新聞稿,宣佈選舉兩名新的獨立董事,即斯里什蒂·古普塔博士和凱文·麥克勞克林,他們將分別擔任薪酬和審計委員會主席。該公司對新任董事在增長時期將帶來的專業知識表示熱情,尤其是在Invivyd將其首款產品商業化並改進其用於變體分析和預測建模的專有工具之際。新聞稿還強調了美國食品藥品管理局最近授予Invivyd的單克隆抗體的緊急使用授權(EUA),用於免疫功能低下人群的 COVID-19 暴露前預防,這標誌着該公司的一個重要里程碑。
2024年5月21日,生物製藥公司Invivyd, Inc. 舉行了年度股東大會,選出了七名董事,任期一年。當選董事包括塔姆辛·貝里、薩拉·科特、馬克·埃利亞、醫學博士斯里什蒂·古普塔、克里斯汀·林登布姆、泰倫斯·麥奎爾和凱文·麥克勞克林。此外,股東批准任命普華永道會計師事務所爲該公司截至2024年12月31日的財政年度的獨立註冊會計師事務所。會後,Invivyd發佈了一份新聞稿,宣佈選舉兩名新的獨立董事,即斯里什蒂·古普塔博士和凱文·麥克勞克林,他們將分別擔任薪酬和審計委員會主席。該公司對新任董事在增長時期將帶來的專業知識表示熱情,尤其是在Invivyd將其首款產品商業化並改進其用於變體分析和預測建模的專有工具之際。新聞稿還強調了美國食品藥品管理局最近授予Invivyd的單克隆抗體的緊急使用授權(EUA),用於免疫功能低下人群的 COVID-19 暴露前預防,這標誌着該公司的一個重要里程碑。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。